LivaNova PLC Stock: price and management transactions · United States · SEC (Form 4)

About LivaNova PLC

LivaNova PLC is a U.S.-listed medical technology company traded on Nasdaq under the ticker LIVN, with its corporate headquarters in London and a broad international operating footprint, including the United States. For French-speaking investors, it is best understood as a focused healthcare device company rather than a broad diversified medtech conglomerate. Its portfolio is concentrated in high-value, regulated niches where clinical expertise, reimbursement dynamics, installed base economics and physician adoption are central to long-term competitiveness. The company traces its roots to a combination of legacy medical-device businesses built over decades, and it has since evolved into a more streamlined platform focused on two core pillars: epilepsy neuromodulation and cardiopulmonary systems. Its flagship neurology therapy is VNS Therapy, an implantable vagus nerve stimulation treatment used primarily for drug-resistant epilepsy, with a potential broader opportunity in depression and other neuromodulation indications. On the cardiovascular side, LivaNova supplies cardiopulmonary and perfusion technologies used in cardiac surgery and related hospital procedures, including the Essenz perfusion platform. The group is also building an additional growth vector in obstructive sleep apnea through the aura6000 system, which expands its exposure beyond its traditional core franchises. From a competitive standpoint, LivaNova occupies a niche but strategically attractive position. It does not compete on scale alone; rather, its moat is built on product specialization, regulatory know-how, clinical relationships, hospital integration and a long product cycle. In epilepsy, the company benefits from a differentiated therapy category and increasing evidence generation. In cardiopulmonary, it remains a meaningful supplier of mission-critical systems used in complex surgical environments. This focused structure supports margin potential, but the business remains sensitive to reimbursement decisions, regulatory approvals, product liability risks and clinical uptake. LivaNova’s key products and services therefore include VNS Therapy, cardiopulmonary and perfusion systems, and emerging digital/remote monitoring capabilities linked to its treatment platforms. Geographically, the company is global, with operations across North America, Europe and Asia, and a workforce of roughly 3,300 employees in 34 countries as of year-end 2025. Recent milestones have included double-digit revenue growth, raised guidance, improved U.S. Medicare reimbursement for VNS Therapy procedures, FDA approval for a cloud-based digital health platform, and U.S. approval for aura6000 in moderate-to-severe obstructive sleep apnea. For international equity investors, LivaNova represents a specialized medtech name combining defensive healthcare characteristics with innovation-driven upside and execution-sensitive growth potential.